References

1. 1.
   ZHAN M，XU H，YU G，et al.Androgen receptor deficiency-induced TUG1 in suppressing ferroptosis to promote benign prostatic hyperplasia through the miR-188-3p/GPX4 signal pathway［J］.Redox Biol，2024，75：103298.
2. 2.
   GBD 2019 Benign Prostatic Hyperplasia Collaborators.The global，regional，and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019：A systematic analysis for the Global Burden of Disease Study 2019［J］.Lancet Healthy Longev，2022，3（11）：e754-e776.
3. 3.
   LI T，ZHANG Y，ZHOU Z，et al.Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia［J］.Biol Direct，2024，19（1）：61.
4. 4.
   LI N，YANG K，DENG L，et al.Mendelian randomization study supports positive bidirectional causal relationships between genetically predicted insomnia symptom and liability to benign prostatic hyperplasia［J］.BMC Urol，2024，24（1）：91.
5. 5.
   LO RE M，POLVERINO P，RIVETTI A，et al.Transperineal laser ablation（TPLA） of the prostate for benign prostatic obstruction：The first 100 patients cohort of a prospective，single-center study［J］.World J Urol，2024，42（1）：402.
6. 6.
   GONG Y J，ZHANG Q，ZHU Y X，et al.Meta-analysis of Yishen Huayu formula combined with tamsulosin hydrochloride in the treatment of benign prostatic hyperplasia ［J］.Chin J of New Drugs，2024，33（9）：942-951.
7. 7.
   LI G S，GAO D W，CHANG D G.Exploring the pathogenesis and treatment of benign prostatic hyperplasia based on the theory of meridians and collaterals［J］.Chin J Androl，2023，37（4）：97-100.
8. 8.
   LI S L，LU G G，JIN G W，et al.Advances in basic and clinical research of traditional Chinese medicine in the treatment of benign prostatic hyperplasia［J］.Chin J Integr Med，2024，49（21）：5817-5828.
9. 9.
   XU W，BAI M，MIAO M S.Exploring the medication patterns and potential mechanisms of drug action in benign prostatic hyperplasia based on data mining and network pharmacology［J］.Chin J Pharmacol Clin，2021，37（2）：191-198.
10. 10.
    CHEN X，SONG J，YUAN D，et al.Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/Akt pathway in benign prostatic hyperplasia［J］.Biosci Rep，2021，41（6）：BSR20210477.
11. 11.
    GAO X，HU W，QIAN D，et al.The mechanisms of ferroptosis under hypoxia［J］.Cell Mol Neurobiol，2023，43（7）：3329-3341.
12. 12.
    DA SILVA S ，BARBOZA O M，SOUZA J T，et al.Structural design，synthesis and antioxidant，antileishmania，anti-inflammatory and anticancer activities of a novel quercetin acetylated derivative［J］.Molecules，2021，26（22）：6923.
13. 13.
    CHOI J Y，FAN M，WEDAMULLA E N，et al.Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway［J］.Food Sci Human Well，2024，13（3）：1698-1710.
14. 14.
    HOU Q，ZHENG D X，GENG R Y，et al.Exploring the effects of Huatie Wan on the prevention and treatment of benign prostatic hyperplasia through the PI3K/Akt signaling pathway based on network pharmacology and animal experiments［J］.Chin Tradit Pat Med，2024，46（7）：2355-2364.
15. 15.
    HU J H，LEI L J，ZHAO P，et al.Investigating the effects of Kongzhuang decoction on benign prostatic hyperplasia in rats through the PI3K/Akt signaling pathway［J］.Chin J Exp Form，2022，28（19）：89-96.
16. 16.
    MENG F C，LI H S，ZHAO Q，et al.Observational study on the efficacy of Lingze tablets in the clinical application for benign prostatic hyperplasia in real-world settings［J］.Chin J Androl，2021，35（4）：40-44.
17. 17.
    KUANG H，PENG A J，WANG J S，et al.Investigating the intervention mechanism of Lingze tablets on benign prostatic hyperplasia in rats based on the PI3K/Akt pathway［J］.Chin J Androl，2023，37（4）：54-58，66.
18. 18.
    HUANG S，WANG K，HUANG D，et al.Bisphenol AF induces prostatic dorsal lobe hyperplasia in rats through activation of the NF-κB signaling pathway［J］.Int J Mol Sci，2023，24（22）：16221.
19. 19.
    LALLE G，TWARDOWSKI J，GRINBERG-BLEYER Y.NF-κB in cancer immunity：Friend or foe？［J］.Cells，2021，10（2）：355.
20. 20.
    MIRZAEI S，SAGHARI S，BASSIRI F，et al.NF-κB as a regulator of cancer metastasis and therapy response：A focus on epithelial-mesenchymal transition［J］.J Cell Physiol，2022，237（7）：2770-2795.
21. 21.
    KO Y S，PYO J S，CHO W J.Roles of NF-κB activation in benign prostatic hyperplasia and association between NF-κB and HIF-1α［J］.Pathol Res Pract，2022，237：154021.
22. 22.
    WANG K Y.Regulatory effect of NF-κB on prostatic hyperplasia：Progress in researches［J］.Nat J Androl，2021，27（11）：1025-1029.
23. 23.
    PARK D H，PARK K H，YIN J，et al.Inhibitory activities of dimeric ellagitannins isolated from Cornus alba on benign prostatic hypertrophy［J］.Molecules，2021，26（11）：3446.
24. 24.
    HWANG B，KIM J，PARK S，et al.Ethanol extracts of Cornus alba improve benign prostatic hyperplasia by inhibiting prostate cell proliferation through modulating 5 alpha-reductase/androgen receptor axis-mediated signaling［J］.World J Mens Health，2024，42（4）：830-841.
25. 25.
    JIN B R，AN H J.Oral administration of berberine represses macrophage activation-associated benign prostatic hyperplasia：A pivotal involvement of the NF-κB［J］.Aging（Albany NY），2021，13（16）：20016-20028.
26. 26.
    YANG J Y，HU Y L，ZHAO Y N，et al.Exploring the medication patterns and mechanisms of action of Gardenia in the prevention and treatment of benign prostatic hyperplasia based on data mining and network pharmacology，with experimental validation［J］.Chin Hosp Pharm J，2025，45（5）：546-553..
27. 27.
    ZANG L，TIAN F，YAO Y，et al.Qianliexin capsule exerts anti-inflammatory activity in chronic non-bacterial prostatitis and benign prostatic hyperplasia via NF-κB and inflammasome［J］.J Cell Mol Med，2021，25（12）：5753-5768.
28. 28.
    SHEN T，WANG W，ZHOU W，et al.MAPK4 promotes prostate cancer by concerted activation of androgen receptor and Akt［J］.J Clin Invest，2021，131（4）：e135465.
29. 29.
    YAN Y，DAI T，GUO M，et al.A review of non-classical MAPK family member，MAPK4：A pivotal player in cancer development and therapeutic intervention［J］.Int J Biol Macromol，2024，271（Pt 2）：132686.
30. 30.
    WANG K.Expression and significance of mitogen-activated protein kinases（MAPK） in benign prostatic hyperplasia tissue ［D］.Shenyang：China Medical University，2004.
31. 31.
    SONG X，SONG Q，WANG R，et al.The mechanism of the anti-androgenic effect of tetrahydroxynonene on prostate cancer［J］.Chin J Androl，2023，29（5）：402-408.
32. 32.
    CALMASINI F B，DE OLIVEIRA M G，ALEXANDRE E C，et al.Obesity-induced mouse benign prostatic hyperplasia（BPH） is improved by treatment with resveratrol：Implication of oxidative stress，insulin sensitivity and neuronal growth factor［J］.J Nutr Biochem，2018，55：53-58.
33. 33.
    LI C，HU W L，LU M X，et al.Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line（BPH-1） through p38 MAPK-FOXO3a pathway［J］.BMC Complement Altern Med，2019，19（1）：233.
34. 34.
    LI H F，MENG S，WANG X X，et al.Exploring the mechanisms of compound Huiqin granules in the treatment of benign prostatic hyperplasia based on network pharmacology and experimental validation［J］.Chin J Integr Trad West Med，2022，44（9）：3041-3047.
35. 35.
    LIHUA J，HAODAN K，YUAN X U.Efficacy of Buzhong Yiqi decoction on benign prostatic hyperplasia and its possible mechanism［J］.J Tradit Chin Med，2023，43（3）：533-541.
36. 36.
    LIU Y.Study on the inhibitory effect of Dan Zhi Qing E decoction on autoimmune inflammation-induced benign prostatic hyperplasia in rats ［D］.Tianjin：Tianjin University of Traditional Chinese Medicine，2023.
37. 37.
    JAHAN N，CHOWDHURY A，LI T，et al.Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway［J］.Redox Rep，2021，26（1）：1-9.
38. 38.
    TAN G X，CHEN Y M，YU M Z，et al.The inhibitory effect of berberine hydrochloride on benign prostatic hyperplasia in rats and its impact on the Nrf2/ARE pathway［J］.Chin J Androl，2022，28（1）：9-13.
39. 39.
    ZHANG L，XIE H，YAN M，et al. The effects of Ke Long capsules on the rat model of benign prostatic hyperplasia and the Nrf2/ARE signaling pathway［J］. Chin J Exp Tradit Med Form，2018，24（11）：87-91.
40. 40.
    ZHENG M，ZHENFAN W，CHEN X，et al. Shikonin alleviates testosterone-induced benign prostatic hyperplasia in rats via the Nrf2-ARE and NF-κB pathway［J］.Mol Cell Toxicol，2022，20（1）：1-7.
41. 41.
    FU W，CHEN S，ZHANG Z，et al. Quercetin in Tonglong Qibi decoction ameliorates testosterone-induced benign prostatic hyperplasia in rats by regulating Nrf2 signalling pathways and oxidative stress［J］.Andrologia，2022，54 （9）：e14502.
42. 42.
    VICKMAN R E，FRANCO O E，MOLINE D C，et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia：A review［J］.Asian J Urol，2020，7 （3）：191-202.
43. 43.
    CAI R J，XU M. KHSRP regulates the response of prostate cancer cells to androgens through ANK3［J］. J Shanghai Jiao Tong Univ （Med Sci），2024，44（4）：417-426.
44. 44.
    LIU N，LIU X Y. Research progress on the androgen/AR signaling pathway in benign prostatic hyperplasia. Chin J Cell Biol，2020，42（9）：1669-1675.
45. 45.
    PARK W Y，SONG G，PARK J Y，et al. Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3［J］.Cell Death Dis，2022，13 （6）：554.
46. 46.
    JANG Y J，JUNG H Y，MYEONG J Y，et al. Effects of alginate oligosaccharide on testosterone-induced benign prostatic hyperplasia in orchiectomized rats［J］.Nutrients，2023，15 （3）：682.
47. 47.
    JIN B R，KIM H J，NA J H，et al. Targeting benign prostate hyperplasia treatments：AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation［J］.J Adv Res，2024，57：135-147.
48. 48.
    LIU S J，WANG F，GAO Q H，et al. Therapeutic effects and mechanisms of Ningmi Tai capsules on a rat model of benign prostatic hyperplasia［J］. Chin Tradit Herb Drug，2023，54（16）：5267-5273.
49. 49.
    LUO H. Correlation of FGF2 and TGF-β₁ with benign prostatic hyperplasia：Progress in research［J］.Nat J Androl，2022，28（9）：843-847.
50. 50.
    ABUDUSHALAMU A，YANG F. Research progresses of effect of TGF-β₁/Smads signaling pathway on urinary tract diseases［J］.J Clin Urol，2018，33（4）：331-333.
51. 51.
    CAO Y，TIAN Y，ZHANG H，et al. Imbalance in the estrogen/androgen ratio may affect prostate fibrosis through the TGF-β/Smad signaling pathway［J］.Int Urol Nephrol，2022，54 （3）：499-508.
52. 52.
    YANG P，HUANG Q J，LI X X，et al. Research progress on the pharmacological effects and mechanisms of hesperidin［J］. Chin Tradit Herb Drug， 2023，54（21）：7222-7231.
53. 53.
    KIM H J，JIN B R，AN H J. Hesperidin ameliorates benign prostatic hyperplasia by attenuating cell proliferation，inflammatory response，and epithelial-mesenchymal transition via the TGF-β₁/Smad signaling pathway［J］.Biomed Pharmacother，2023，160：114389.
54. 54.
    YU J，ZHANG X，WANG J，et al. Diterpene glycosides from Fructus Rubi ameliorates benign prostatic hyperplasia in rats through the androgen and TGF-β/Smad signaling pathway［J］.J Ethnopharmacol，2025，337（Pt 1）：118756.
55. 55.
    YE B，MAI P Y，ZHU M，et al. The effects of Qianlie Xiaotang on the proliferation and apoptosis of prostate fibroblasts in experimental autoimmune prostatitis mice by regulating the TGF-β₁/Smad4 and Smad7 signaling pathways［J］. Chin J Androl，2020，26（7）：631-638.
56. 56.
    CHEN W，HUANG X，PENG A，et al. Kangquan recipe regulates the expression of BAMBI protein via the TGF-β/Smad signaling pathway to inhibit benign prostatic hyperplasia in rats［J］.Evid Based Complement Alternat Med，2019，2019：6281819.
57. 57.
    YANBO C，HUAN X，QILING S， et al.Hypoxia-inducible factor 1α （HIF-1α） mediates the epithelial-mesenchymal transition in benign prostatic hyperplasia［J］.Int J Clin Exp Pathol，2019，12（1）：295-304.
58. 58.
    ZHANG T，MAO C，CHANG Y，et al. Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line：A mechanism for the pathogenesis of benign prostatic hyperplasia［J］.Curr Urol，2024，18 （3）：185-193.
59. 59.
    HAO L，WANG X T，PAN T J，et al. Clinical efficacy of Guizhi Fuling capsules in the treatment of benign prostatic hyperplasia［J］. Chin J Androl，2020，34（5）：51-54.
60. 60.
    ZHANG Y P，WANG H M，XIE X，et al. Study on the mechanisms of Guizhi Fuling capsules in inhibiting benign prostatic hyperplasia［J］. Drug Evaluat Res，2023，46（7）：1472-1479.
61. 61.
    ZHAO F，YE M Y，ZHANG C H. Exploration of the inhibitory effects and mechanisms of Qizhi Tongqiao capsules on testosterone-mediated prostate hyperplasia in rats［J］. Chin J Androl，2022，36（6）：19-24.
62. 62.
    DENG Y J，GAO Q H，LIU S J，et al. Study on the mechanisms of Xia Liqi capsules in the treatment of benign prostatic hyperplasia based on network pharmacology［J］. Chin Tradit Herb Drug，2021，52（6）：1681-1686.
63. 63.
    TU Y L，CHEN Q H. Effects of Yishen Tonglong capsules on the estrogen-androgen ratio and hypoxia-inducible factor-1α in a rat model of benign prostatic hyperplasia［J］. J Hunan Univ Tradit Chin Med，2020，40（1）：14-17.